15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Viking Therapeutics Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $65.00 to $125.00, a moderate spread. The average target of $99.57 sits 196% above the current $33.67. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.10 next quarter toward $-4.32 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Viking Therapeutics Inc.
As of Sep, 7 of 7 firms rate VKTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VKTX EPS & revenue forecast
EPS · NEXT QUARTER
$-1.10
Range $-1.48 – $-0.67 · 16 analysts · -20% YoY
Next period, 16 analysts expect Viking Therapeutics Inc to earn $-1.10 a share (range $-1.48 – $-0.67), versus $-1.38 a year earlier. Full-year consensus is $-4.61, growing to $-4.32 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 16 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Viking Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VKTX.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$96.00+185.1% to target
Overall win rate
50%
+ Follow
#2
Roger Song
Jefferies · Rank #101
Buy
$101.00+200.0% to target
Overall win rate
43%
+ Follow
#3
George Farmer
Scotiabank · Rank #240
Buy
$102.00+202.9% to target
Overall win rate
44%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$102.00+202.9% to target
Overall win rate
34%
+ Follow
#5
Jay Olson
Oppenheimer · Rank #360
Buy
$100.00+197.0% to target
Overall win rate
33%
+ Follow
VKTX stock forecast FAQ
What is VKTX's average 12-month price target?+
The 7 analysts with a live target average $99.57 for Viking Therapeutics Inc over the next 12 months, ranging from a $125.00 high to a $65.00 low.
Is VKTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VKTX?+
The Street-high target is $125.00 (BTIG), and the Street-low is $65.00 (JP Morgan). The average of all 7 active targets is $99.57.
How many Wall Street analysts cover VKTX?+
7 analysts have an active rating on Viking Therapeutics Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering VKTX?+
Among analysts who currently cover VKTX, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $96.00 target.
What is Viking Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.10 per share (range $-1.48 – $-0.67) across 16 analysts. Full-year EPS is projected at $-4.61, rising to $-4.32 the following year.
How much revenue is Viking Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading VKTX lately?+
As of Sep, 7 of 7 firms rate VKTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VKTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
